Last reviewed · How we verify
NCT04698291
Genetic Variants and Regulation of Specialized Pro-resolving Mediator
trial testing Blood Donation in Healthy in 200 participants. Currently enrolling.
5 October 2027
Quick facts
| Lead sponsor | Queen Mary University of London |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 6 May 2021 |
| Primary completion | 5 October 2027 |
| Estimated completion | 8 December 2027 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Blood Donation
Conditions studied
- Healthy — all drugs for Healthy →
- Inflammatory Disease — all drugs for Inflammatory Disease →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
Queen Mary University of London
Who can join
18 and older, any sex, with Healthy or Inflammatory Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Inflammation is the way that the body reacts against infection, injury or illness. An uncontrolled inflammatory response can lead to the development of inflammatory diseases, such as rheumatoid arthritis and cardiovascular conditions. Recent studies have shown that inflammation is a regulated process coordinated by a group of molecules known as specialized pro-resolving mediator (SPM). These molecules are produced by enzymes via the enzymatic conversion of essential fatty acids; whereas their biological actions are mediated by proteins expressed on the surface of cells known as receptors. Given the central role that pro-resolving mediators play in regulating the immune response, the aim of this study is to investigate whether there are genetic variants (mutations) in genes encoding for enzymes and receptors involved in the biology of these molecules and to determine how these mutations affect SPM's activity or function. Findings made as part of these studies will help shed light into mechanism influencing disease onset and/or progression and potentially enhance the discovery of new and more effective treatments.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators.
Perez-Hernandez J, Chiurchiù V, Perruche S, You S. · · 2021 · cited 33× · PMID 34868025 · DOI 10.3389/fimmu.2021.768133 -
Pro-resolving lipid mediators in diseases: exploring the molecular basis and clinical implication.
Li C, Wang Z, Yang Y, Jiang Q, et al · · 2026 · PMID 41486400 · DOI 10.1186/s43556-025-00400-5
Verify or expand the search:
- PubMed search for NCT04698291
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood Donation
Trials testing the same drug.
- NCT05869747 — Firefighter Collaborative Research Project · NA · active not recruiting
- NCT04060589 — ReIMAGINE Prostate Cancer Risk · unknown
- NCT03696797 — Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease · NA · completed
- NCT03348020 — Iron and Insulin Resistance in Overweight and Obese Humans · NA · completed
- NCT01681420 — Improving Blood Safety and HIV Testing in Brazil · NA · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Queen Mary University of London trials
Trials by the same sponsor.
- NCT07246005 — LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus · Phase 2 · not yet recruiting
- NCT07165678 — CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2) · NA · not yet recruiting
- NCT06937372 — Delivery and Implementation of a Randomised Crossover Trial on Thrombosis · NA · not yet recruiting
- NCT06600438 — Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial · NA · not yet recruiting
- NCT06987045 — Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04698291 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Queen Mary University of London
- Last refreshed: 5 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04698291.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing